Macroporous Bioactive Glass Scaffold Pore Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing macroporous bioactive glass scaffolds are limited by high production costs, difficulty in controlling composition and pore size, and inadequate mechanical strength, which hinders their effectiveness in tissue repair and engineering applications.
Innovation Solution
A new method using glass powders with organic pore-forming agents and processing techniques like dry pressing molding or gelation-casting, allowing for controlled pore size, porosity, and compressive strength within a range of 1-16 MPa, while promoting bioactivity and degradability through controlled crystallization of calcium phosphate and silicate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Shape
If hot-pressing approach using inorganic salts as pore-forming agents is used to prepare macroporous bioactive glass scaffolds, then the scaffolds can be produced with macroporous structure, but the production cost increases and composition control becomes difficult
Solution Approach 1:
The patent replaces expensive inorganic salts with cheap organic pore-forming agents such as starch, cellulose, or polyethylene glycol. These organic materials serve as temporary placeholders that are removed during sintering, leaving behind pores. This substitution significantly reduces material costs and simplifies composition control while achieving the desired macroporous structure.
Solution Approach 2:
The patent controls pore size and distribution by adjusting parameters such as the size and concentration of organic pore-forming agents, sintering temperature (700-900°C), and pressing pressure. By optimizing these parameters, the method achieves precise control over the macroporous structure without the complexity associated with inorganic salt-based approaches.
2Reliability
If sintering temperature of 1000°C is used to prepare 45S5 bioactive glass scaffolds with oxydol as foaming agent, then the scaffolds achieve bioactivity and bone bonding ability, but the glass becomes substantially crystallized and resorbability decreases
Solution Approach 1:
The patent reduces the sintering temperature from 1000°C to a range of 700-900°C, which prevents substantial crystallization of the glass matrix while still achieving adequate bioactivity. This temperature optimization maintains the amorphous structure necessary for high resorbability and degradation rates, while the macroporous structure provides sufficient surface area for bone bonding.
Solution Approach 2:
The patent creates a macroporous structure with pore sizes of 50-500 microns that enhances both bioactivity and resorbability. The porous structure increases the surface area available for bone apposition and cellular interaction, compensating for the lower sintering temperature, while simultaneously providing pathways for fluid penetration and degradation product removal.
3Adaptability or versatility
If macroporous bioactive glass scaffolds are used for tissue engineering applications, then the scaffolds can serve as cell carriers and promote tissue regeneration, but the mechanical strength is inadequate and the scaffolds are prone to breakage
Solution Approach 1:
The patent produces composite structures by combining bioactive glass particles with organic pore-forming agents and binding materials. This composite approach creates a dual-phase structure where the glass particles provide bioactivity and the matrix structure provides mechanical support, achieving both tissue regeneration capability and adequate mechanical strength.
Solution Approach 2:
The patent optimizes the porosity and pore size distribution (50-500 microns) to balance mechanical strength and biological function. The interconnected pore structure provides pathways for nutrient transport and waste removal while maintaining sufficient structural integrity to support cell growth and prevent scaffold collapse during the tissue regeneration process.
4Manufacturing precision
If pore size is reduced to enhance cell housing and tissue in-growth, then the bonding to living tissues improves, but the mechanical strength of the scaffold decreases
Solution Approach 1:
The patent creates a heterogeneous pore size distribution within the scaffold, with smaller pores (50-200 microns) in regions requiring enhanced cell housing and tissue bonding, and larger pores (200-500 microns) in regions requiring mechanical support and fluid transport. This local optimization of pore sizes allows the scaffold to simultaneously achieve good bonding and adequate strength.
Solution Approach 2:
The patent uses composite construction with bioactive glass particles embedded in a matrix, creating a hierarchical structure that provides both fine pores for cell interaction and larger voids for structural support. This multi-scale porous architecture enables the scaffold to fulfill both biological and mechanical requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting macroporous bioactive glass scaffolds exhibit excellent bioactivity, controlled degradability, and mechanical strength, enabling effective tissue repair and in vitro bone tissue culture with enhanced biointerfaces and resorbability.
Implementation Method 1
A new method using glass powders with organic pore-forming agents and processing techniques like dry pressing molding or gelation-casting, allowing for controlled pore size, porosity, and compressive strength
Implementation Method 2
promoting bioactivity and degradability through controlled crystallization of calcium phosphate and silicate
Implementation Method 3
Dr. Larry Hench reported that such glass could bond together with bone tissues for the first time... this glass can bring along not only the benefit of osteoconduction, but also the bioactivity to stimulate the growth of bone tissues
Data Source
AI summary
A resorbable, macroporous bioactive glass scaffold comprising approximately 24-45% CaO, 34-50% SiO2, 0-25% Na2O, 5-17% P2O5, 0-5% MgO and 0-1% CaF2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.